Holen Sie sich die Stockscreener-App
0.9999
2.01%
0.0199
Schlusskurs vom Vortag:
$0.98
Offen:
$0.978
24-Stunden-Volumen:
321.33K
Relative Volume:
0.41
Marktkapitalisierung:
$87.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.4739
EPS:
-2.11
Netto-Cashflow:
$-71.16M
1W Leistung:
+8.89%
1M Leistung:
-13.07%
6M Leistung:
-35.50%
1J Leistung:
-15.28%
1-Tages-Spanne:
$0.96
$1.03
1-Wochen-Bereich:
$0.91
$1.03
52-Wochen-Spanne:
$0.8319
$2.11
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Vergleichen Sie IMUX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.9999 | 87.97M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.93 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.54 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.40 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.75 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
B. Riley Reaffirms Buy Rating for Immunic (NASDAQ:IMUX) - Defense World
HC Wainwright Has Optimistic View of Immunic FY2025 Earnings - Defense World
HC Wainwright Estimates Immunic’s Q1 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st
Immunic Stock Price, Quotes and Forecasts | NASDAQ:IMUX - Benzinga
Immunic, Inc. Announces Closing of $5.1 Million Registered Direc - GuruFocus
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode - MSN
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - The Malaysian Reserve
Immunic Closes of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - citybiz
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - Eastern Progress
Immunic Raises $5.1 Million From Direct Stock Offering - marketscreener.com
Immunic Lands Strategic $5.1M Financing Deal: Aberdeen Investments Takes Lead Position - Stock Titan
Immunic closes $5.1M placement - Proactive financial news
Immunic announces pricing of $5.1M registered direct offering - MSN
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direc - GuruFocus
Immunic Announces $5.1 Million Securities Purchase Agreement - MSN
Immunic sets $5.1 million stock offering price By Investing.com - Investing.com Canada
Immunic sets $5.1 million stock offering price - Investing.com Australia
Immunic announces pricing of $5.1M direct offering to support clinical pipeline - Proactive financial news
Immunic Announces Pricing Of $5.1 Million Registered Direct Offering - marketscreener.com
Immunic Lands $5.1M Institutional Backing: Aberdeen Investments Takes Major Stake - Stock Titan
What is Leerink Partnrs’ Estimate for Immunic Q1 Earnings? - Defense World
Immunic (NASDAQ:IMUX) Earns “Buy” Rating from D. Boral Capital - The AM Reporter
Immunic (NASDAQ:IMUX) Given “Buy” Rating at D. Boral Capital - Defense World
Immunic to present at AAN 2025 and German Biotech Days in April - Proactive financial news
Immunic, Inc. to Participate in Scientific and Industry Conferences in April - The Malaysian Reserve
Immunic's Game-Changing MS Treatment Takes Center Stage at Two Global Conferences - Stock Titan
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic CMO discusses significance of MS Awareness Month; progress with treatment - Proactive financial news
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages - Defense World
Immunic Therapeutics: Interview With CEO Dr. Daniel Vitt About The Inflammatory And Autoimmune Diseases Therapy Company - Pulse 2.0
180 Life Sciences (NASDAQ:ATNF) versus Immunic (NASDAQ:IMUX) Head to Head Comparison - Defense World
Immunic (NASDAQ:IMUX) Now Covered by Analysts at William Blair - Defense World
Immunic (NASDAQ:IMUX) Now Covered by William Blair - The AM Reporter
William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation - Nasdaq
William Blair sees Immunic stock outperforming on RMS therapy By Investing.com - Investing.com Australia
How did Immunic Inc (IMUX) fare last session? - uspostnews.com
William Blair sees Immunic stock outperforming on RMS therapy - Investing.com
Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky - Yahoo Finance
William Blair Initiates Immunic at Outperform With $6.80 Price Target - MarketScreener
Buy Rating on Immunic Driven by Promising CALLIPER Study Outcomes and Market Opportunities in Progressive Multiple Sclerosis - TipRanks
Immunic’s Vidofludimus Calcium: A Promising Disruptor in the $45 Billion Multiple Sclerosis Market - TipRanks
StockNews.com Downgrades Immunic (NASDAQ:IMUX) to Sell - Defense World
Immunic provides MS research update – ICYMI - Proactive Investors Australia
Immunic (NASDAQ:IMUX) Raised to “Hold” at StockNews.com - Defense World
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):